A patient once told me he’d stopped going swimming with his kids because he didn’t want anyone staring at the plaques covering his arms and legs. He’d tried topical steroids, light therapy, even methotrexate, but nothing got his psoriasis under control for long. When his dermatologist started him on Cosentyx, he came back to the pharmacy a few months later wearing short sleeves for the first time in years. That kind of turnaround is exactly why IL-17 inhibitors like Cosentyx have become a key treatment option for moderate to severe plaque psoriasis today.
What Cosentyx Actually Is
Cosentyx is the brand name for secukinumab, a biologic medication that works by binding directly to interleukin-17A, commonly written as IL-17A, and neutralizing it before it can trigger the inflammatory cascade that drives psoriasis. It belongs to a class of drugs known as IL-17 inhibitors, which represent one of the most effective targeted therapies available for patients with moderate to severe disease.
Why IL-17 Is the Right Target
To understand why blocking IL-17A matters so much, it helps to understand what it does in psoriasis. IL-17A is a cytokine produced largely by a subset of immune cells called Th17 cells, and in psoriasis, it drives the rapid, abnormal turnover of skin cells that produces the thick, scaled plaques characteristic of the disease. According to the National Psoriasis Foundation, this overactive IL-17 signaling is now understood to be one of the central drivers of psoriasis, which is part of why drugs targeting this single pathway have proven so effective compared to older, broader treatments.
By binding to IL-17A and preventing it from interacting with its receptor, secukinumab interrupts the inflammatory cycle at its source, reducing inflammation and slowing abnormal skin cell turnover rather than just treating visible symptoms on the surface.
What the Evidence Shows
The clinical evidence behind Cosentyx is substantial. The pivotal ERASURE and FIXTURE trials, published in the New England Journal of Medicine, found that a majority of patients treated with secukinumab achieved significant skin clearance, measured using the PASI scoring system that dermatologists use to track plaque severity, with many patients reaching near complete or complete clearance of their plaques. These results were notably stronger than what older systemic treatments typically achieved.
Beyond the initial response, durability matters too. A review in the Journal of the American Academy of Dermatology noted that patients who respond well to secukinumab in the first several months tend to maintain that response over extended treatment periods, which is critical for a chronic condition requiring long-term control rather than short-term relief.
How Quickly It Works
One of the things patients ask me most often is how soon they’ll actually notice a difference. Clinical trial data has shown that many patients begin seeing improvement within the first few weeks of starting secukinumab, with itching and redness often easing before plaques have fully cleared. Maximum results typically build over twelve to sixteen weeks of consistent treatment. That timeline matters for setting realistic expectations, since patients who expect overnight results sometimes get discouraged before the drug has had a chance to work.
How It’s Taken
Secukinumab is given as a subcutaneous injection. Most patients start with a loading phase of weekly doses for the first month, followed by a maintenance schedule of one injection every four weeks. Many patients are trained to self-administer the injections at home using a prefilled pen or syringe, which makes long term treatment far more convenient and sustainable than frequent clinic visits.
Beyond Psoriasis
Cosentyx isn’t limited to plaque psoriasis. It’s also approved for psoriatic arthritis and ankylosing spondylitis, two conditions that share the same underlying IL-17 driven inflammatory pathway. Research published in The Lancet has highlighted how this shared mechanism makes IL-17 inhibitors useful across a cluster of related inflammatory conditions, particularly for patients dealing with both skin and joint symptoms.
Where It Fits Among Biologic Options
Secukinumab isn’t the only targeted option for psoriasis. IL-23 inhibitors like risankizumab work further upstream in the same inflammatory pathway, and other IL-17A inhibitors like ixekizumab offer a similar mechanism with some differences in dosing and trial outcomes. Choosing between them often comes down to dosing frequency, prior treatment response, and whether a patient also has joint symptoms. While several biologics now offer high clearance rates, secukinumab remains one of the most established and widely used options in this class. I’ll be comparing these options head-to-head in upcoming articles, but secukinumab was one of the first IL-17 inhibitors to establish just how effective this class of targeted therapy could be.
Safety Considerations Worth Knowing
Because IL-17 also plays a role in the body’s natural defense against certain fungal infections, one of the more distinctive side effects associated with secukinumab is an increased risk of mucocutaneous candidiasis, generally mild fungal infections of the skin or mouth. The British Journal of Dermatology has noted that while these infections are usually manageable with standard antifungal treatment, patients should be aware of the connection so they can flag symptoms early. In most cases, early recognition makes these side effects straightforward to treat.
Other safety considerations include the standard precautions that come with most biologics: screening for latent tuberculosis before starting treatment, monitoring for signs of infection, and caution in patients with inflammatory bowel disease, since IL-17 inhibition has been associated with new or worsening symptoms in some patients with that condition.
The Bottom Line
Secukinumab represents a clear example of what targeted immune therapy can achieve when it’s aimed at the right pathway. For patients with moderate to severe psoriasis who’ve cycled through topical treatments and older systemic options without lasting relief, IL-17 inhibitors like Cosentyx have shifted what’s realistically achievable, not just symptom control, but genuinely clear skin for a meaningful stretch of time.
If you’re living with psoriasis that hasn’t responded well to standard treatment, it may be worth discussing IL-17 inhibitors like Cosentyx with your dermatologist as a next step option for better long-term control.
FAQs
Q1: What is Cosentyx used for?
Cosentyx (secukinumab) is approved for moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking IL-17A, a key driver of inflammation in all three conditions.
Q2: How does Cosentyx work?
Cosentyx binds to and neutralizes IL-17A, a cytokine that drives the rapid skin cell turnover and inflammation behind psoriasis plaques, interrupting the disease process at its source.
Q3: How long does it take for Cosentyx to work?
Many patients notice improvement within the first few weeks, with maximum skin clearance typically building over twelve to sixteen weeks of consistent treatment.
Q4: How is Cosentyx administered?
Cosentyx is given as a subcutaneous injection: weekly for the first month, then once every four weeks for maintenance. Most patients self-inject at home using a prefilled pen.
Q5: What are the side effects of Cosentyx?
The most notable side effect is an increased risk of mild fungal infections like oral or skin candidiasis, since IL-17 also helps the body fight fungal infections naturally. Other risks include injection site reactions and increased infection susceptibility.
Q6: Is Cosentyx safe for long term use?
Clinical data shows patients who respond well tend to maintain that response over extended treatment periods. It requires regular monitoring, including screening for latent tuberculosis before starting.
Q7: Who should not take Cosentyx?
Cosentyx isn’t recommended for people with active infections, and it should be used cautiously in patients with inflammatory bowel disease, since IL-17 inhibition has been linked to new or worsening IBD symptoms in some patients.
Q8: How does Cosentyx compare to other IL-17 inhibitors like Taltz?
Cosentyx and Taltz both target IL-17A but differ in dosing schedules and some trial outcomes. The right choice often depends on treatment history and whether joint symptoms are also present.
Explore More on PharmaHealths
For more on how biologics target the immune pathways behind psoriasis and eczema, check out my Complete Immunology Guide on PharmaHealths.com, where I compare Cosentyx with Dupixent, Skyrizi, and other targeted treatment options.
Disclaimer
This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your doctor, dermatologist, or pharmacist before starting, stopping, or changing any treatment.
References
• National Psoriasis Foundation
• New England Journal of Medicine
• Journal of the American Academy of Dermatology
• The Lancet
• British Journal of Dermatology